News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma’s CFO to leave the company in December 2017

September 15, 2017

PledPharma AB
Company Announcement

PledPharma’s CFO to leave the company in December 2017

Stockholm, 2017-09-15 08:00 CEST (GLOBE NEWSWIRE) -- 
PledPharma today announced that Michaela Gertz has decided to leave the company
after seven years as Chief Financial Officer. 

Michaela Gertz, part of PledPharma’s Management Team, has been employed since
2010. She will leave her position in December 2017. 

"PledPharma has undergone a growth journey from a project in the early clinical
phase to a company with two projects in clinical development of which one is
heading into registration studies. Michaela has been an important part of the
management team that built PledPharma and I would like to thank her for her
valuable contributions and wishing her all the best in her future career, "says
PledPharma’s CEO Nicklas Westerholm. 

"It has been exiting and developing to take part in and contribute to
PledPharmas's journey for seven years, not least in the execution of the
company's IPO. I now look forward to apply my experience to a new exciting
challenge.” Says PledPharma’s CFO Michaela Gertz 

For more information, please contact:

Nicklas Westerholm, CEO, phone: +46 73 354 20 62

Michaela Gertz, CFO, phone: +46 709 26 17 75

About PledPharma
PledPharma develops new drugs that protect the body against oxidative stress –
a potentially debilitating and sometimes life-threatening condition that can be
caused by chemotherapy treatment and following acetaminophen (paracetamol)
overdose. The company's most advanced project PledOx® is being developed to
reduce nerve damage associated with chemotherapy. A phase IIb study has been
conducted and will serve as the basis for the continued development. The drug
candidate Aladote® is being developed to reduce the risk of acute liver failure
associated with acetaminophen poisoning. PledPharma (STO: PLED) is listed on
Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel
+46 8 463 80 00). For more information, see



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10